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Abstract
Long‐term survival for children who undergo LT is now the rule rather than the ex‐
ception. However, a focus on the outcome of patient or graft survival rates alone pro‐
vides an incomplete and limited view of life for patients who undergo LT as an infant, 
child, or teen. The paradigm has now appropriately shifted to opportunities focused 
on our overarching goals of “surviving and thriving” with long‐term allograft health, 
freedom of complications from long‐term immunosuppression, self‐reported well‐
being, and global functional health. Experts within the liver transplant community 
highlight clinical gaps and potential barriers at each of the pretransplant, intra‐op‐
erative, early‐, medium‐, and long‐term post‐transplant stages toward these broader 
mandates. Strategies including clinical research, innovation, and quality improvement 
targeting both traditional as well as PRO are outlined and, if successfully leveraged 
and conducted, would improve outcomes for recipients of pediatric LT.
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1  | INTRODUC TION
The first LT was performed by Thomas Starzl in 1963 on a 2‐year‐old 
child with biliary atresia, proving that hepatic replacement surgery 
was technically feasible.1 Effective immunosuppression, improved 
technical expertise enabling technical variant grafts and LDLT,2 and 
expanded therapies to prevent infection are a few examples of key 
contributors to improved 5‐year patient and graft survival rates up‐
wards of 90%.3 However, survival metrics provide an incomplete 
and limited view of life after LT in infants, children, teens, and young 
adults. The emerging paradigm is now appropriately shifted to op‐
portunities focused on enhancing the health span, defined as the 
length of time that a pediatric recipient is alive and functionally well 
following transplantation. At 10 years after LT, less than 1/3 of pe‐
diatric recipients registered in the SPLIT registry are considered to 
be in “ideal or optimal health,” as defined by (a) normal liver tests; (b) 
maintenence immunosuppression monotherapy; (c) normal growth; 
and (d) free of significant immunosuppression‐associated comorbid 
conditions.4 Of note, this ideal outcome estimate is almost certainly 
optimistic given emerging findings highlighting that consistently 
normal results of liver tests “do not tell the whole story” and may in 
fact hide a spectrum of subclinical pathology that can only be accu‐
rately revealed by histopathological examination of tissue provided 
by a liver biopsy. 5‐7 The goals of pediatric LT mandate targeted strat‐
egies to ensure children thrive as well as survive. However, pediatric 
LT management and care is challenging and highly specialized, with 
psychosocial development during the adolescent years adding par‐
ticular complexities. Research is limited by the power of study size, 
logistical impediments of being integrated within larger or complex 
hospital systems, and eventual transfer of care to adult transplant 
centers. Subsequent barriers to collaboration include geospatial 
location, current metrics of clinical productivity, matrix reporting 
structures, increasing regulatory requirements and demands for 
professional advancement.8
A group of experts in the LT community identified and summa‐
rized key barriers which, if successfully leveraged and conducted, 
would optimize the unpredictable and often circuitous journey for 
young children with irreversible liver disease for whom LT offers 
the only chance for long‐term survival. This manuscript proposes 
constructs to guide a path forward in addressing these barriers and 
advancing pediatric LT care.
1.1 | Journey of the pediatric patient
Each child who is evaluated and accepted as a candidate for LT 
embarks on a unique journey with potential obstacles and hurdles 
which may challenge attainment of the end goal of sustainable 
long‐term health (Figure 1). This journey to best outcomes must 
traverse a broad landscape, with multiple phases beginning with 
listing decisions, addressing predictable challenges pretransplant, 
F I G U R E  1   Journey	of	the	patient	following	pediatric	Liver	Transplantation	–	Key	Factors	Contributory	to	Desired	Outcomes.	HRQOL,	
Health related Quality of Life; PROM, Patient Reported Outcome Measure
Minimize Comorbidites on Wait List 
•Allocation policy 
•Accurate risk stratification 
•Frailty 
•Sarcopenia 
•Matching organs to patients 
Optimize Sustainable Health
•Allograft Health
•Complications of Long-Term immunosuppression
•PROM tools and HRQOL assessment
•Transition and Transfer
•Health of Parents and /or Care-Providers
Enhance Early Graft Function
•Surgical Complications
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• Infections
•Variations in immunosuppression approaches
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•Support of extra hepatic systems
•Operative techniques
•Anesthesia considerations
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and the recovery process with continuous learning and adapta‐
tion to care during the post‐transplant course. The combinations 
of challenges are unique for each patient. Timely listing requires 
early recognition of LT responsive disease conditions, easy access 
to LT care, and fulfillment of LT center listing criteria. Once listed, 
the goals shift to surviving the wait list without incurring signifi‐
cant morbidity until a suitable donor organ is available. Variations 
in allocation policies and physician organ acceptance behavior and 
practices exist among countries and between LT centers.9 Once the 
“right” donor liver is identified, the patient must undergo the LT 
operation and peri‐operative phases, prior to navigating the early‐, 
medium‐, and long‐term post‐transplant follow‐up care phases. 
Multiple elements of each phase of care will inform graft function, 
which are instrumental and contributory to optimizing both life 
span and health span for pediatric LT recipients. The best patient‐
centered outcomes reflect a complex care cycle in which each in‐
tervention is dependent on the effectiveness of previous decisions 
and interventions, with active participation toward optimizing the 
child's overall health before and after LT.
1.2 | Timely listing for all pediatric LT candidates
1.2.1 | Access to care and candidate selection
Despite formal guidelines for the evaluation and selection of the 
pediatric LT patient endorsed by the AASLD, AST, and NASPGHAN,10 
empirical evidence suggests that there is substantial variation among 
listing decision‐making among centers.11 There are more than 30 
pediatric liver transplant centers in the United States and three 
pediatric programs in Canada that performed five or more pediat‐
ric LT in the calendar year 2018 (https ://optn.trans plant.hrsa.gov/
data/view‐data‐repor ts/build‐advanced, accessed March 17, 2019). 
The travel distance from the patient's home to the LT center varies 
greatly. Potential contributors limiting access include insurance type, 
and racial and gender disparities.11
The more common indications for LT including biliary atresia, 
autoimmune liver disease, and genetic disorders of intrahepatic 
cholestasis for LT are generally readily identified by referring phy‐
sicians although delayed diagnoses continue to challenge. There is 
a lack of objective metrics to assess non‐hepatic morbidity for in‐
herited defect of metabolism, especially in those conditions not as‐
sociated with structural liver disease. Whether LT is indicated for 
inherited disorders of metabolism, cystic fibrosis, liver fibrosis as‐
sociated with congenital heart disease and complex hepatic tumors, 
among others, may be challenging to determine since decision‐mak‐
ing requires coordination of care across disciplines.12‐14 Delays are 
particularly critical since insults during the early years impact brain 
development, growth, and long‐term functional health, as well as 
vulnerabilities specific to pediatrics.15 The expanding indications of 
pediatric liver diseases amenable to LT, the relatively small number 
of pediatric patients, and the challenges of extrapolating adult data 
to children challenge prognostication. Indeed, the expected 90‐day 
mortality using the PELD underestimated the actual probability of 
death by as much as 17%.16 Additional considerations impacting can‐
didate selection include individual center medical and surgical ex‐
perience, clinical decision‐making, resource allocation, execution of 
the operational standards, and impact of center‐specific outcomes 
reported to the public domain.17
Recommendations
• Characterize factors contributing to delays in referral of pediatric 
patient to LT centers.
• Develop strategies to mitigate the barriers to timely access to LT 
centers for pediatric patients with indications for LT.
• Develop a strategy to track outcomes for those who are not se‐
lected as LT candidates.
• Standardize selection criteria within and among pediatric centers.
1.2.2 | Decreasing time duration and minimizing 
comorbidities on the wait list
The impact of wait time duration and the ensuing comorbidities are 
not equivalent between developing children and adults. Children 
with irreversible liver disease offer a more complex challenge since 
crucial and time‐limited opportunities for growth, cognitive, neuro‐
logical, and social development are lost with increasing wait list du‐
ration leading to more procedures and hospitalizations for medical 
therapies and need for prehabilitation optimization strategies.
1.2.3 | Allocation
In the United States, the PELD score is used to prioritize children on 
the wait list. Since its implementation, additional points for children 
are available either by automatic granting of “standard exception 
points” for a list of consensus conditions, or by petitioning for indi‐
vidual case‐by‐case “NSER” by pediatric LT program submitting nar‐
ratives explaining why a calculated PELD score does not accurately 
reflect mortality or morbidity risk for a specific patient. Currently, 
there is lack of standardization in NSER utilization overall. However, 
NSER denial increases the risk of wait list mortality or removal from 
the wait list for being too sick.18 Despite 5%‐10% yearly increases in 
organ donation and concurrent increments in total transplants per‐
formed annually, death or “removal for too sick to transplant” rates 
range from 7% to 12% on the pediatric LT wait list,19,20 while the 
number of pediatric LTs performed yearly has remained relatively 
fixed. The feasibility of a decrease in pediatric wait list deaths, con‐
current with an overall increase in LTs performed, was recently dem‐
onstrated in a liver simulated allocation model analysis prioritizing 
pediatric plus the sickest (Status 1) adult patients for deceased donor 
livers utilizing data from the SRTR.21
Recommendations
• Optimize organ allocation policies and develop risk stratification 
systems to improve access and reduce wait list mortality among 
children.
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1.2.4 | Distribution
The disparity of requests and approval for exception is sobering, 
with patients of white race and private insurance more likely to 
benefit. Receiving an exception translated into a nearly 3‐fold in‐
creased likelihood of transplantation.22 Organ acceptance rates 
and utilization of technical variant organs from deceased donors 
also vary among pediatric LT centers, which may further impact 
the risk for children. Racial disparities in access to LT have been 
attributed to multi‐factorial causes including biologic, socio‐eco‐
nomic, and cultural factors.11 There is disparity in use of excep‐
tions by race that is not explained by clinical disease severity, 
primary diagnosis, geography, or other demographic factors.22 
Understanding the presence and ultimately the root causes of 
these disparities in pediatric LT will enhance opportunities to 
save the lives of more children on the wait list. DDLT remains the 
standard of care for LT in North American centers. The demand 
for feasible DD livers far exceeds the available supply, and oppor‐
tunities for LDLT to be used more widely by pediatric LT programs 
are warranted to reduce or eliminate wait list deaths, improve 
time to transplant, and ultimately improve long‐term outcomes 
for children in need of LT.2
Recommendations
• Develop methodologies targeting disparities in timely access to 
quality organs in pediatric transplantation.
• Track outcomes of live donor LT by pediatric transplant programs, 
including wait list deaths, time to transplant, and comorbidities 
from shortened time to transplant surgery, including LT with livers 
from anonymous donors.
1.3 | Enhancing risk stratification of patients on the 
wait list
The “state of health” of children with end‐stage liver disease on the 
wait list is influenced not only by the severity of their liver disease, 
but also by factors such as nutritional status, functional impair‐
ments, and non‐liver related comorbidities including renal failure 
or cardiopulmonary disease. These latter factors contribute to wait 
list outcomes, yet are not well captured by the PELD score. Recent 
review of two‐dimensional echocardiographic findings in listed chil‐
dren with biliary atresia demonstrates that cirrhotic cardiomyopathy 
is independently associated with serious adverse events and peri‐
transplant death.23 The biologic construction of physical frailty, orig‐
inally developed in the field of geriatrics, has been shown to capture 
the effects of end‐stage liver failure in adults (“relative chronologic 
youth”) and predict post‐transplant outcomes and morbidity.24‐26 
The concept of frailty has been extended to children, with a recent 
study demonstrating feasibility of testing for the five domains of the 
Fried Frailty Phenotype in a multicenter cohort of children between 
the ages of 5 and 18 years with chronic liver disease, with 46% meet‐
ing the criteria for frailty at a single baseline assessment.27 However, 
the majority of wait listed children are under the age of 5 years, and 
thereby too young to undergo functional or performance‐based 
(frailty) testing before time of LT. Pilot sarcopenia studies have dem‐
onstrated that children with end‐stage liver disease have smaller 
psoas muscle areas on CT abdominal imaging than healthy age‐
matched controls, and that the psoas muscle area does not correlate 
with weight z‐scores nor PELD score. 28,29
Recommendations
• Develop validated and objective pediatric tools and non‐invasive 
biomarkers to more fully capture global functional health, nutri‐
tional status, and neurocognitive development.
• Develop more accurate metrics that portend risk beyond those 
provided by measures of liver injury and function, prioritizing high 
yield areas of frailty, sarcopenia, and non‐invasive biomarkers 
which may aid risk stratification of children and adolescents on 
the liver transplant wait list.
1.4 | Minimizing risks during the intra‐ and peri‐
operative phases
Minimizing complications in the intra‐operative and early post‐oper‐
ative periods requires effective decision‐making in patient selection 
and the organ to be used. Critical components include preoperative 
medical evaluation and optimization of the recipient's health prior to 
LT (including avoiding delays of childhood immunizations), simulta‐
neous coordination and execution of the donor and recipient opera‐
tions, and the effective medical management of the patient in the 
operating room and post‐operatively in the PICU. In aviation safety 
research, many if not all fatal crashes were root‐caused to a prevent‐
able complication of poor communication, execution, or problem 
recognition, 30,31 concepts that extend to peri‐operative graft loss 
or patient mortality.32 For instance, both duration of extubation and 
length of PICU stay are actionable determinants that could decrease 
overall length of stay, mitigate risk, and minimize wastage of valuable 
resources.33,34 In order to optimize outcomes following LT, clinicians 
must adopt approaches to not only prevent complications, but also 
to successfully salvage patients after complications occur.35 While 
some complications may not be preventable, the ability to rapidly 
diagnose and “rescue” a patient from a complication (minimizing 
the rates of FTR) relates to the quality of care of the health by the 
healthcare system. This strategy can help identify important areas 
for outcome improvements across centers and is emerging as a use‐
ful quality improvement tool for the pediatric LT field.36
Recommendations
• Develop checklists of intra‐operative events and their timing 
that could predict the likelihood that a patient will progress as 
expected in their post‐operative care versus requiring subsequent 
planned or unplanned operations that may prolong recovery.
• Identify center practice variations in peri‐operative and PICU care 
and minimize failure‐to‐rescue rates.
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1.5 | Long‐term health after LT
1.5.1 | Allograft health
Meticulous management of immunosuppression is required to en‐
sure the best long‐term outcomes for all LT recipients. In pediat‐
rics, this theme is uniquely challenging given the goal of multiple 
decades of graft and patient survival. “Too little” immunosuppres‐
sion risks chronic and often subclinical alloimmune injury, while 
“too much” immunosuppression risks insidious and cumulative 
toxicities and comorbidities affecting extra‐hepatic organ sys‐
tems. Immunosuppression after pediatric LT is dominantly driven 
by program preference, although patient or donor characteristics 
clearly affect initial regimen choice.37 Children, with their longer 
life expectancy, experience greater cumulative exposure to immu‐
nosuppressive agents, thereby increasing their potential morbid‐
ity from these agents. While immunosuppression minimization or 
withdrawal has been a strategy adopted in response to the devel‐
opment of PTLD and other serious comorbidities, the literature 
is also revealing for many single‐center reports of operationally 
tolerant patients—defined as those with serially normal liver func‐
tion tests and serum transaminase levels. Evaluation of allograft 
dysfunction is complex. Biochemical markers of graft injury have 
variable sensitivity and specificity, and histological evidence of 
graft injury may be present even with concurrent normal liver 
test results.5,6 Chronic allograft injury, both inflammation and/or 
fibrosis, was reported in a multicenter cohort of stable, long‐term 
pediatric LT recipients with consistently normal results from liver 
tests.7 Complications following protocol liver biopsies performed 
in post‐pediatric LT recipients were infrequent and resolved 
quickly, with biopsy‐related cholangitis occurring only in those 
patients with underlying biliary strictures.38 Liver biopsies suf‐
fer from variable interpretation and sampling error, while imaging 
studies are insensitive.38,39 Clinical trials are needed to determine 
predictors of successful immunosuppression withdrawal to allow 
for personalization of medication regimens.
Recommendations
• Develop biomarkers that can be used to identify tolerance, graft 
injury, and injury mechanism(s).
• Assess the effects of immunosuppression personalization on 
patient outcomes and costs, including targeted therapy to miti‐
gate graft injury before the development of irreversible allograft 
damage.
1.5.2 | Metrics beyond the graft
Measuring outcomes after pediatric LT requires a focus beyond ex‐
amining only easily accessible data from national administrative or 
even multicenter clinical databases. An appreciation of the insuffi‐
cient spotlight to‐date on patient centeredness is increasingly being 
recognized across multiple chronic conditions including adult trans‐
plant recipients.40 In pediatrics, understanding what is important 
and most meaningful to our pediatric patients also mandates atten‐
tion to their parents and siblings, transition planning and commu‐
nity support. This will also impact the quality of life years restored, 
including the multi‐dimensional elements of health status, wellness, 
vitality, and perceptions of quality of life.
After the first year post‐LT, pediatric LT recipients move into 
a chronic management phase in which the primary goal shifts to 
sustained graft health without comorbidities or sequelae from 
long‐term immunosuppression. Based on this premise, a com‐
posite description of ideal health status in pediatric long‐term 
follow‐up patients was derived using the SPLIT database, laying 
the foundation for future initiatives to focus beyond individual 
risks of known complications and identify broader sets of out‐
comes at earlier stages.4 An additional emerging theme in health 
care is recognition of the impact of condition on emotional or 
functional disabilities as reported by patients. PROs are defined 
as “any report of the status of a patient's health condition that 
comes directly from the patient, without interpretation of the pa‐
tient's response by a clinician or anyone else.”41 Patient Reported 
Outcome Measure tools (PROMs) that enable assessment of 
patient‐reported health status for physical, mental, and social 
well‐being have been catalogued within the National Institute 
of Health's Roadmap Network Project called Patient Reported 
Outcomes Measurement Information system (PROMIS).42 
Disease‐specific health‐related quality of life (HRQOL) tools for 
pediatric LT are now available and may inform us about challenges 
from the patients and family perspective that can be leveraged 
to guide and improve care and facilitate research efforts.43 In 
response to the parents’ request for pre‐emptive and system‐
atic assessment of the “patient voice” at follow‐up ambulatory 
LT clinic visits by the Patient Advocacy Working Group in the 
newly formed SNEPT, a learning network that engages families 
and providers, six pediatric LT programs are currently piloting the 
feasibility of systemic administration of, the first pediatric liver 
transplant‐specific quality of life tool (Pediatric Liver Transplant 
Quality of Life, PeLTQL®)43 into the clinic environment.44
Recommendation
• Incorporate validated PROMs into the surveillance plans of long‐
term pediatric LT survivors to amplify the patient voice and focus 
targets for intervention strategies.
• Leverage currently accumulating registry data and advanced an‐
alytics to define composite outcomes and inform targets for im‐
provement within pediatric LT.
1.5.3 | Non‐adherence
Non‐adherence with immunosuppressive medication remains the 
most frequent cause for late allograft rejection and a leading cause 
of organ loss and morbidity in children and adolescents who have 
undergone LT.45 Understanding the long‐term trajectory of non‐
adherence to immunosuppression medications can inform deci‐
sions regarding liver allocation, adherence monitoring, long‐term 
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graft health, and targeting intervention efforts. Interventions 
targeting self‐management skills have been effective in improv‐
ing medication adherence in other pediatric chronic illness groups, 
with the challenge being time and resource constraints. The de‐
mand for the use of technology (such as mobile health and others) 
to address the barriers associated with non‐adherence facilitates 
the acquisition of the skills needed to independently manage med‐
ication regimens.46 Despite a growing recognition of this issue, 
there is currently no internationally accepted or “gold standard” 
method to assess IS adherence. A recent prospective multicenter 
study found that MLVI is associated with late acute rejection in 
pediatric LT recipients.47
Recommendations
• Further, validate and implement broader use of MLVI and other 
tools to identify at‐risk non‐adherent patients for interventional 
strategies.
• Develop collaborative partnerships with healthcare innovators 
and learning networks to enhance the assessment and delivery of 
strategies that measure and mitigate non‐adherence.
1.5.4 | Transition and transfer from pediatric to 
adult transplant care
The transition from pediatric to adult‐centered health care is part of the 
developmental process for those with chronic childhood diseases and 
disabilities.46 The AST has highlighted transition as an obstacle to long‐
term graft health for pediatric organ transplant recipients.48 Uninformed 
transition and transfer practices may negatively impact successful self‐
management, adherence, and—ultimately—graft survival.49‐51
Recommendations
• Perform studies that define metrics of a “successful” transition.
• Develop partnerships between pediatric and adult teams to ad‐
dress the domains of self‐management and transition readiness.
2  | SUMMARY
Emerging models in organizational behavior and learning networks 
provide ample opportunities for our community to explore and in‐
vest in, with the goal of decreasing the time from discovery and 
acquisition of new knowledge to action and impact in pediatric LT. 
Successful strategies must address problems based on an under‐
standing of the outcomes (metrics) and the gaps between actual 
and desired outcomes, decision‐making (determining how best to 
address the gap), execution of meaningful research, and policy 
development or improvement. Figure 2 provides a summary of 
recommendations and strategies targeting currently identified bar‐
riers encountered in the survive and thrive journey traversed by a 
pediatric LT candidate.
To address the challenges encountered by patients, families, 
and the healthcare team alike, multi‐institutional collaborations 
have developed strategies to drive awareness, to focus research 
efforts, and to target quality improvement measures that supple‐
ment regulatory efforts in the pediatric LT population. The Studies 
F I G U R E  2   Summary of recommendations
Access
Characterize delays in referral to 
pediatric LT centers.
Develop strategies to mitigate
barriers to timely access to LT
Develop pediatric tools and non-invasive biomarkers targeting global functional health, nutritional status, and neurocognitive development of the patients.  
Use of validated tools to identify at-risk non-
adherent patients to enhance interventional 
strategies.
Develop biomarkers to identify tolerance, injury and 
injury mechanisms.
Track outcomes of 
children not selected 
as LT candidates 
Develop partnerships between pediatric and adult teams to 
address self-management and transition readiness. 
Standardize selection 







on the wait list
Address disparities on the wait list
Prioritize high yield themes (frailty, sarcopenia, extra-
hepatic organs, cardiac function and non-invasive 
biomarkers) to augment  pediatric risk stratification
Assess immunosuppression personalization on 
patient/graft outcomes and costs
Practice Variation
Develop checklists for intra- and peri-
operative phases and events to facilitate 
ability to predict and prevent unplanned and 
anticipated complications
Identify center practice variations in peri-
operative and PICU care and minimize
Failure to Rescue rates.  
Define metrics of a “successful” 
transition 
Incorporate validated PROMs 
into surveillance plans
Pre-Transplant Peri-Transplant Early Post Transplant Late Post Transplant
Track LDLT (include anonymous) outcomes in pediatric transplant programs
Biomarkers
Develop collaborative partnerships with health care 
innovators and learning networks to assess and 
mitigate non-adherence. 
Patient Centered Innovation
Leverage current registry data and advanced analytics to define composite outcomes and inform targets for improvement within pediatric LT.
     |  7 of 8NG et al.
in Pediatric Liver Transplantations consortium founded in 1995 
recently incorporated, formally changed its name to become The 
Society of Pediatric Liver Transplantation (enabling retention of its 
long‐standing acronym—SPLIT), acquired tax‐exempt status with 
a 501c(3), and become the newest section of The Transplantation 
Society (https ://www.tts.org/split/ about‐us‐split ). SPLIT remains 
unwaveringly committed to addressing the many unanswered ques‐
tions and opportunities illuminated by the barriers articulated in this 
manuscript. The SPLIT Registry (https ://secure.emmes.com/emme‐
sweb) will continue to be the foundational resource to support fu‐
ture initiatives within the SPLIT mission to improve the outcomes in 
children receiving LT through research, quality improvement, edu‐
cation, advocacy, active engagement of patient and engaged part‐
ners/stakeholders, and mentorship of the next generation of clinical 
care providers and investigators.
The newly formed SNEPT (www.starz ltran splan tnetw ork.com) 
with its mission “to unite big data, technology, patient advocacy and 
transplant thought leaders to deliver the best possible care and de‐
velop new, scalable solutions to pediatric transplantation's most 
challenging problems” is a key partner in furthening the SPLIT mis‐
sion and vision52,53 Collaborative efforts within the LICOP, Pediatric 
Subcommittee, American Society of Transplantation‐PCOP, and other 
stakeholder organizations will be vital in order to move the field for‐
ward. We propose an integrated approach of targeted research and 
policy changes to ensure the best outcomes for this patient population.
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